| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.0021 | 0.9 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | lomeguatrib | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.0023 | 0.9 |